Cargando…

Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States

BACKGROUND: Metastatic prostate cancer is initially sensitive to androgen receptor inhibition, but eventually becomes metastatic castration-resistant prostate cancer (mCRPC). Olaparib has longer progression-free survival and better measures of response and patient-reported end points than either enz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Chenxia, Cai, Jiaqin, Zhuang, Jie, Zheng, Bin, Chen, Li, Sun, Hong, Zheng, Guiyan, Wei, Xiaoxia, Liu, Maobai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403933/ https://www.ncbi.nlm.nih.gov/pubmed/36034977 http://dx.doi.org/10.21037/atm-22-3637

Ejemplares similares

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States
por: Liu, Maobai, et al.
Publicado: (2019)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kan, et al.
Publicado: (2021)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
por: A’Hern, Roger, et al.
Publicado: (2011)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
por: Nogueira Costa, Inês, et al.
Publicado: (2022)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
por: Alameddine, Zakaria, et al.
Publicado: (2023)

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib
por: Gong, Lifeng, et al.
Publicado: (2022)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
por: Karzai, Fatima, et al.
Publicado: (2018)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
por: LeVee, Alexis, et al.
Publicado: (2021)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
por: VanderWeele, David J., et al.
Publicado: (2015)

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
por: Shore, Neal D., et al.
Publicado: (2021)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Publicado: (2021)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
por: Kim, Joseph W., et al.
Publicado: (2023)

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials
por: Luo, Zhanyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l3bjmbsm4hv90msh6tvprc1gn9